Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Sit up for a moment before standing to give your body time to adjust
Pfizer's danuglipron, once considered the primary competitor, was discontinued in April 2025 after a case of potential drug-induced liver injury in a dose-optimization study, following the earlier termination of lotiglipron in 2023 for similar hepatic concerns
Serious Warnings: GLP-1 receptor agonists carry a boxed warning regarding thyroid C-cell tumors observed in animal studies
Treatment with the combination drug also delayed the need for insulin therapy
US$ 26.94
US$ 27.37
US$ 24.59
US$ 21.62
US$ 25.31
US$ 29.34
US$ 28.79
US$ 29.89
